Reduction of gastrointestinal tract colonization by *Klebsiella quasipneumoniae* using antimicrobial protein Kvarla

Indre Karaliute¹, Rima Ramonaite¹, Jurga Bernatoniene², Vilma Petrikaite³, Audrius Misiunas⁴, Erna Denkovskiene⁴, Ausra Razanskiene⁶, Yuri Gleba⁵, Juozas Kupcinskas¹,⁶ and Jurgita Skieceviciene*¹

**Abstract**

**Background:** *Klebsiella quasipneumoniae* is an opportunistic pathogen causing antibiotic-resistant infections of the gastrointestinal tract in many clinical cases. Orally delivered bioactive *Klebsiella*-specific antimicrobial proteins, klebicins, could be a promising method to eradicate *Klebsiella* species infecting the gut.

**Methods:** Mouse infection model was established based on infection of antibiotic-treated BALB/C mice with *K. quasipneumoniae* strain DSM28212. Four study groups were used (3 animals/group) to test the antimicrobial efficacy of orally delivered klebicin Kvarla: vehicle-only group (control, phosphate-buffered saline), and other three groups with bacteria, antibiotic therapy and 100 µg of uncoated Kvarla, 100 µg coated Kvarla, 1000 µg coated-Kvarla. Because of the general sensitivity of bacteriocins to gastroduodenal proteases, Kvarla doses were coated with Eudragit®, a GMP-certified formulation agent that releases the protein at certain pH. The coating treatment was selected based on measurements of mouse GI tract pH. The quantity of *Klebsiella* haemolysin gene (*khe*) in faecal samples of the study animals was used to quantify the presence of *Klebsiella*.

**Results:** GI colonization of *K. quasipneumoniae* was achieved only in the antibiotic-treated mice groups. Significant changes in *khe* marker quantification were found after the use of Eudragit® S100 formulated klebicin Kvarla, at both doses, with a significant reduction of *K. quasipneumoniae* colonization compared to the vehicle-only control group.

**Conclusions:** Mouse GI tract colonization with *K. quasipneumoniae* can be achieved if natural gut microbiota is suppressed by prior antibiotic treatment. The study demonstrates that GI infection caused by *K. quasipneumoniae* can be significantly reduced using Eudragit®-protected klebicin Kvarla.

**Keywords:** *Klebsiella quasipneumoniae*, Klebicins, Kvarla, Haemolysin gene, Bacteriocins

**Background**

*Klebsiella* is a gram-negative and facultative anaerobic bacterium of the *Enterobacteriaceae* family that colonizes various environmental niches including normal flora of the human mouth or intestines [1, 2]. Pathogenic *Klebsiella* species, such as *K. pneumoniae* and *K. oxytoca*, are the most prevalent infections acquired in hospital (HAI) [2, 3]. Recent studies have identified *K. quasipneumoniae* as a new species distinguishable from *K. pneumoniae*. *K. quasipneumoniae* has been shown to act as an etiological agent in a number of clinical *Klebsiella*-related infection cases, but has often been misidentified as *K. pneumoniae* in HAI [4, 5]. *K. quasipneumoniae* colonizes the intestinal tract, which...
can lead to virulent urinary tract and abdominal infections [3–6]. Furthermore, this type of bacteria shows high rates of resistance against antibiotics, and some strains have been characterized as pan-drug resistant, making these infection extremely difficult to treat [7, 8]. For this reason, the development of new antimicrobial agents is required to mitigate bacterial infections, typically acquired by patients while in-hospital.

Colicin-like bacteriocins, produced by gram-negative bacteria, may be a potential alternative to traditional antibiotics [9, 10]. Colicin-like bacteriocins are a heterogeneous family of proteinaceous toxins, which are capable of killing closely related bacteria, those belonging to the same species or, sometimes, the same genus [11]. This property makes them attractive as therapeutics since they offer a more targeted approach than conventional antibiotics. Indeed, one of the major issues with conventional antibiotics is the dysbiosis induced by the broad-range killing of bacteria [12, 13]. Most importantly, the mechanisms of bacterial killing by bacteriocins are fundamentally different from those by antibiotics. Consequently, they are active against multi-drug and pan-drug resistant pathogens.

The authors have previously identified and characterized several *Klebsiella* colicin-type bacteriocins, klebicins, which exhibit significant and broad activity against the pathogenic *Klebsiella* species. Orally delivered klebicins have a potential as an excellent means to eradicate intestinal infections in hospitalized patients that are caused by the multidrug-resistant *Klebsiella* strains. However, the proteinaceous nature of bacteriocins makes them susceptible to quick inactivation by gastroduodenal enzymes. Therefore, for the oral administration of klebicins, they must be encapsulated or formulated for gastroduodenal protection, for the release in the small and large intestine.

In this study, the possibility to use klebicins to eradicate intestine colonizing Klebsiella was tested in K. quasipneumoniae–Kvarla model. Klebicin Kvarla is pore forming bacteriocin, highly active against *K. quasipneumoniae* [14]. We developed a mouse model of *K. quasipneumoniae* intestinal colonization, tested the pH condition of the mouse GI tract, and established a suitable coating for klebicin Kvarla. We also evaluated the antimicrobial activity of the orally delivered Eudragit S100-formulated klebicin in the mouse intestinal tract. We confirmed that, even without further bacteriocin engineering and improvement, bacteriocins could be employed as oral antimicrobials for efficient control of antibiotic-resistant *Klebsiella*.

**Methods**

**Aim of this study**

To investigate the antimicrobial effectiveness of the klebicin Kvarla in a mouse model of *K. quasipneumoniae* gastrointestinal (GI) colonization.

**Mouse models**

Two different animal study designs were used for *K. quasipneumoniae* colonization and Kvarla treatment. For both studies, 8–10 weeks old, BALB/c strain, female (n=8; 19–25 g) and male (n=16; 22–27 g) mice were purchased from the Lithuanian University of Health Sciences vivarium of laboratory animals. All regulated procedures on living animals were approved by The Lithuanian Ethics Committee of Biomedical Research (Protocol no. G2-119).

**GI model of *K. quasipneumoniae* (DSM28212) colonization and Kvarla therapy**

*Klebsiella quasipneumoniae* clinical isolate DSM28212 was used for GI tract colonization in four different study groups containing three mice per group (m=2; f=1). Vehicle-only control group was monitored for any changes in the natural host-microbiota without any additional procedures during the period of the experiment. The ability of *K. quasipneumoniae* to colonize the GI tract without antibiotic pre-treatment to disrupt the host-microbiota was tested. In order to mimic hospital-acquired infections two groups were given different combinations of antibiotic treatment before infection (penicillin (2000 U/ml) + streptomycin (2 mg/ml), (pen_strep); penicillin (2000 U/ml) + streptomycin (2 mg/ml) + metronidazole (1 g/L) (pen_strep_met)) (study design in Fig. 1A). These particular antibiotics were chosen because of their broad mechanism of action against gram-negative and gram-positive bacteria. For Kvarla therapy testing the same composition of antibiotic pre-treatment was used as in the previously described study. Three groups (A; B; C) received 10⁷ cfu of *K. quasipneumoniae* orally by pipette feeding once per day. Afterward, ampicillin (500 mg/l) therapy was used to maintain as low as possible viability of other than *K. quasipneumoniae* bacteria. From day 18th group A was given 100 µg of uncoated Kvarla, groups B and C were given 100 µg and 1000 µg of Eudragit S100-coated Kvarla respectively (detailed study design Fig. 2A). For each mouse, faecal pellets were sampled.

**Determination of pH of the gastrointestinal tract**

As shown in Fig. 1A, the samples of rectum excreta were collected on six different days during the experiment. Acquired samples were homogenized with deionized water (1:10 ratio)
and pH was determined using pH METER Mettler Toledo (Belgium) with the Inlab Ultra-Micro electrode. In addition, the pH was measured in the samples taken from the GI tract during the laparotomy dissection (the intestinal tract was divided into three sections: the stomach, the duodenum, and the rectum).

**Klebicin production in plants and purification**

*Klebsiella* bacteriocin Kvarla was expressed in *Nicotiana benthamiana* transient expression system and purified as previously described in Denkovskiene et al. [14].

**Coating of Kvarla**

5% Eudragit S100 solution was prepared by dissolving 0.5 g Eudragit S100 (Evonik Industries, Germany) in 10 ml of milliQ H2O and by sonication in an ultrasonic bath for 30 min at 25 °C. 250 µg of Kvarla was dissolved in 200 µg of 5% Eudragit S100. The obtained solution was lyophilized at −51 °C for 24 h.

**Simulated gastric digestion and residual Kvarla activity evaluation by soft agar radial diffusion assay**

Protein samples (Kvarla and Eudragit S100-coated Kvarla) were dissolved in simulated gastric buffer (0.15 M NaCl, pH 2), at a concentration of 1 mg/ml and incubated at 37 °C with rotation at 200 rpm for 10 min. 0.025 mg (80–113 U) of pepsin from porcine gastric mucosa was added to 1 mg of protein (pepsin:protein ratio 1:40). Aliquots of reaction (50 µl) were removed at different time points (0.5 min, 5 min, 10 min, 20 min, 30 min, and 60 min after the addition of the pepsin). Digestions were stopped by raising the pH to 6.5 by the addition of 0.5 M ammonium bicarbonate to inactivate pepsin. The pH of samples was adjusted to 8.0 to get Eudragit S100 coat dissolved. The dilutions of all samples by ratio 1:2 were made in distilled water and 5 µL drops of diluted samples were applied on *K. quasipneumoniae* DSM28212 MHA plates for soft agar overlay assay. Soft-agar overlay assays were performed as described by Denkovskiene et al. [14], with some modifications.

**Nucleic acid extraction and synthesis of the cDNA**

Bacterial DNA and RNA from rectum excrement samples were extracted using the AllPrep PowerFecal DNA/RNA Kit. Up to 100 mg of faeces sample were used for the extraction procedures. The quantity and quality of extracted nucleic acids were evaluated by NanoDrop 2000 (Nanodrop Technologies, Wilmington, DE, USA). Subsequently, cDNA was synthesized using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Lithuania). 18 ng of cDNA was added into the qualitative real-time PCR (qRT-PCR) reaction. All processes were completed upon the manufacturer’s instructions.

**Quantitative assessment of Klebsiella quasipneumoniae using Real-Time–PCR**

The haemolysin gene (*khe*) was chosen as the qualitative marker for *Klebsiella* identification [15, 16]. The
Fig. 1 (See legend on previous page.)
standard curve was created based on DNA samples of *K. quasipneumoniae* (DSM28212) to test the generated primers’ efficiency. DNA-based standard curve. 10^3, 10^5, 10^6, 10^8, and 10^10 CFU of *K. quasipneumoniae* in 200 µl were subjected to DNA extraction with QIAamp Fast DNA Stool Mini Kit (protocol for liquid sample).

During this step, the reaction for the qRT-PCR was performed using TaqMan Universal Master Mix II with UNG, TaqMan probe (5-6FAM-CGCGAACTGGAA GGGCCCG-TAMRA-3), and primers (Forward: 5`-GAT GAAACGACCTGA TTGCATTCC-3`, Reverse: 5`-CCG GGCTGTCCGGATAAG-3` (Applied Biosystems, JAV) following the manufacturer’s recommendations. The amplification of the *khe* gene was determined by ABI Fast 7500 System (Life Technologies, Carlsbad, CA, USA) according to standard protocol. Positive controls for...
DNA and RNA were isolated from *K. quasipneumoniae* and negative—isolated from *Escherichia coli*.

**Statistical analysis**
The data were analysed using nonparametric tests. The difference between the four protocols groups throughout the layout of the experiment were analysed using Student’s independent *t*-test. Independent analyses were carried out using SPSS Version 19.0 and MiniTab 20.1.2 software packages. Results were considered statistically significant when *p* < 0.05 with ±95% confidence intervals.

**Results**

Selection of bacteriocin Kvarla coating by pH measurements along the GI tract

In order to determine the efficient coating and delivery of the klebicins in the GI tract, firstly we performed the pH measurements in faeces and along the GI tract. The pH of the faecal samples is shown in Fig. 1B. The lowest pH was seen after penicillin, streptomycin, and metronidazole treatment. Nonetheless, there was no observation of any statistically significant changes in GI tract pH between groups (average mean ± SD: vehicle-only control group 7.3 ± 0.52; bacterial control group 7.5 ± 0.74; pen_strep group 7.7 ± 0.29; pen_strep_met group 7.4 ± 0.62). The pH levels of the different GI tract sections was also measured after the mouse decapitation (the stomach 3.3 ± 0.92, small intestine 6.5 ± 0.34, the large intestine 7.4 ± 0.42; Fig. 1C) The significant differences in pH measures were found between the vehicle-only control group and pen_strep group (*p* = 0.004) in duodenum, vehicle-only control group and pen_strep_met group (*p* = 0.04) in rectum.

Colonization of mice gut by *K. quasipneumoniae* is achieved only after disruption of natural microflora

The GI tract infection/colonization model was established in mice using *Klebsiella quasipneumoniae*. It was designed to reflect bacterial colonization in the host after the disruption of natural microflora with antibiotic therapy. There was no colonization of *K. quasipneumoniae* observed in the vehicle-only control group. The use of antibiotic pre-treatment ((i) penicillin, streptomycin, or (ii) penicillin, streptomycin, and metronidazole), in order to disrupt the host microbiota, resulted in introduction of *K. quasipneumoniae* (4th day no bacterial counts were found (0 CFU/70 mg); (i) 8th day—5.25 × 10⁶ CFU/70 mg, 11th day—3.01 × 10⁸ CFU/70 mg and (ii) 8th day—5.13 × 10⁸ CFU/70 mg and 11th day—3.89 × 10⁹ CFU/70 mg) (Fig. 2). Our data showed that colonization of mice gut by *K. quasipneumoniae* can be established after eradication of natural gut microflora.

**Eudragit S100-coated Kvarla is partially protected from digestion by simulated gastric fluid**

To find out if Eudragit S100-coated Kvarla is resistant to pepsin digestion, a simulated gastric digestion experiment was performed. Exposures of the proteins to Simulated Gastric Fluid (SGF, commercial acidic pepsin extract) were done using low enzyme-to-substrate ratios in order to increase the stringency and relevance of the digestibility assays. Methods were derived from [17–19].

It appears, that in conditions used (pepsin:protein ratio 1:40), protein coating with Eudragit S100 is able to provide temporal resistance to pepsin digestion. Coated Kvarla demonstrated still detectable activity in agar diffusion assay after 20 min of in vitro gastric digestion, while uncoated Kvarla was inactivated in simulated gastric juice very quickly, and completely lost its activity already after 0.5 min of digestion (Fig. 3). From the SDS-PAGE profile of uncoated Kvarla digestion products, it is apparent that uncoated klebicin in digested by pepsin very rapidly.

**Eudragit S100-coated Kvarla efficiently reduces *K. quasipneumoniae* amount in colon**

We evaluated the effectiveness of Eudragit S100-coated Kvarla (100 µg; 1000 µg) in *K. quasipneumoniae* infection model. Three different combinations of recombinant klebicin were used: uncoated-Kvarla, Eudragit S100-coated Kvarla 100 µg, and Eudragit S100-coated Kvarla 1000 µg. The amplification of the *khe* marker gene was significantly higher in both Eudragit S100-coated Kvarla-treated mice groups than in the control (PBS) and uncoated-Kvarla-treated mice on the last day of the experiment (22nd day), meaning that bacterial counts were lower. As shown in Fig. 4 the bacterial counts were significantly lower after the treatment with Eudragit S100-coated Kvarla 100 µg and 1000 µg in contrast with the samples taken on the first day of bacteriocin administration (18th day). The amounts of *K. quasipneumoniae* changed from 6.3 × 10⁷ CFU/50 mg on the 18th day to 3.9 × 10⁸ CFU/50 mg on the 22nd day (*p* = 0.01) in the Eudragit S100-coated Kvarla 100 µg group and from 4.0 × 10⁷ CFU/50 mg on the 18th day to 1.6 × 10⁸ CFU/50 mg on 22nd day (*p* = 0.009) in the Eudragit S100-coated Kvarla 1000 µg group. No significant changes in bacterial counts were seen in the
vehicle-only control group (PBS) and after the administration of uncoated-Kvarla.

**Discussion**

A rapidly increasing number of antibiotic-resistant and/or highly virulent bacterial strains is a serious challenge...
faced by today’s healthcare system worldwide. Recent studies indicate that patients, with hospital-acquired multidrug-resistant *K. pneumoniae* infection, have a significantly higher risk of developing a subsequent infection caused by identical bacteria [20–23]. *K. quasipneumoniae* were initially thought to be asymptomatic carriage isolates until more recent reports highlighted their potential virulence and increased drug resistance [20–23].

*K. pneumoniae* has been extensively studied in many different animal models, including models for bloodstream infections, pneumonia, liver abscess, digestive and urinary tract infections [24, 25]. On the other hand, little is known about closely related species recently separated from *K. pneumoniae* such as *K. variicola* and *K. quasipneumoniae*. There were only limited animal studies with *K. variicola* such as experiments on the bacteria’s ability to colonize the intestinal tract and the host immune system response against this opportunistic pathogen [26, 27]. *K. quasipneumoniae* has been detected in the clinical settings during hospital infections, however, the species has not been tested in animal efficacy models, and mechanisms of infection by this bacterium are poorly understood. Therefore, the first goal of our study was to establish an animal model of *K. quasipneumoniae* intestinal colonization, in particular, identify the conditions that allow bacteria to successfully grow in the mouse intestinal tract. We demonstrate here that for successful colonization of mice gut by *K. quasipneumoniae*, the disturbance of natural gut microflora using antibiotic pre-treatment is necessary and sufficient.

Bacteria were not detected in the bacterial control group without prior antibiotic treatment (judged by *khe* amplification). Similar findings were observed in other *Klebsiella* mouse models where amoxicillin disruption of the gut microbiota was accompanied required for gut colonization and an enhancement of the virulence of *K. variicola* [27]. Other studies illustrated that mouse models of *K. pneumoniae* and treatment with antibiotics led to changes in the host microbiota and the development of a transient super-shedder phenotype, which displays the enhanced transmission efficiency of bacteria in the GI tract [28, 29]. Allegedly, the natural host microbiota activates the defence mechanisms against *K. quasipneumoniae* and inhibits colonization, whereas reduced microbial diversity might promote the ability to infect. However, the exact mechanisms causing *K. quasipneumoniae* colonization needs further investigation.

It is known that bacteriocins have antimicrobial activities against pathogenic microorganisms [30, 31]. Previous studies have identified various classes of bacteriocins (e.g.: colicin-like bacteriocins, tailocins, peptide microcins) and their potential applications in food technology, treatments of infection, and cancer [32–34]. Earlier, we demonstrated the antibacterial efficacy of *Klebsiella* bacteriocins, klebicins, in vitro using clinical *Klebsiella* isolates. Recombinant pore-forming bacteriocin KvarIa was identified as one of the most active klebicins; it showed the highest activity against *K. quasipneumoniae* strains and was also tested in vivo in a non-mammal animal model, *Galleria mellonella* larvae, demonstrating significant antibacterial effect [14]. In this study, we developed a mouse model of intestinal tract
infection using *K. quasipneumoniae* and evaluated the effectiveness of Eudragit S100-coated Kvarla treatment with the main purpose of investigating the potential of klebicins as a clinical antimicrobials. The obtained results can further be translated to *K. pneumoniae* and other more clinically relevant *Klebsiella* species.

The authors determined the most effective coating for bacteriocin needed for delivery of the highest concentrations of the klebicin to the large colon. The pH in the GI tract is a substantial factor, affecting the solubility and stability of the drug and absorption through the intestinal tract mucosa. It can vary depending on the diet type, fed or fasted states, drugs, microbiota diversity, stress, and daily fluid intake. Henceforth, unsuitable pH causes the precipitation of drugs from the solution or the degradation of labile compounds [35–37]. Correspondingly, an assessment of pH levels in the GI tract was included in our study. We distinguished the increased pH level of the rectum content sample in the *K. quasipneumoniae* colonized mice groups treated with antibiotics. However, mice without antibiotics did not show any change in pH levels. Similar results were obtained by Shimizu and colleagues in ICR mice housed obtaining specific pathogen-free conditions, where the pH of the cecum and colon increased exceedingly in the experimental groups treated with antibiotics [38]. Therefore, the pH measurements of the GI tract were taken into account when choosing the most effective coating for Kvarla delivery.

In this study recombinant bacteriocins Kvarla ability to eliminate the intestinal tract infection was judged using khe gene quantification. We identified that both concentrations (100 µg and 1000 µg) of coated-Kvarla significantly reduced the infection in the GI tract of mice models. However, in our study, we did not achieve full eradication of the *K. quasipneumoniae*. Kvarla was encapsulated with Eudragit S100 releasing klebicin at pH above 7 and administered by oral gavage to infected (*K. quasipneumoniae*) mice. Debatably, klebicin activity could be suppressed or significantly lowered because of the gut microflora disruption or not full eradication, as well as, dependence on the pH level, which can fluctuate throughout the GI tract for various reasons (e.g. fasting state). Recently, a similar study was published describing the use of encapsulated colicins for the eradication of *E. coli* in mice [36]. Colicins encapsulated into hydrogel particles were shown to be released from the protective coat at pH above 5 and reduce colonizing *E. coli* numbers in the gut and in feces, although complete eradication of the pathogen was not achieved [39]. Consequently, further research on klebicin formulation for the most efficient release in the lower intestinal tract is necessary. Importantly, new formulations for oral delivery, preferably using approved formulation agents such as Eudragit, should be studied in validated preclinical animal models to further optimize efficacy of bacteriocins as antibacterials for intestinal infections.

**Conclusions**

This study demonstrated that successful colonization of the mouse intestinal tract by *K. quasipneumoniae* can be achieved but it requires the eradication of gut resident microbiota with an antibiotic. We also evaluated the antimicrobial activity of the orally delivered Eudragit S100-formulated klebicin in the mouse intestinal tract and show that thus formulated bacteriocins could be employed as oral antimicrobials for efficient control of antibiotic-resistant *Klebsiella*.

**Abbreviations**

PBS: Phosphate-buffered saline; GI: Gastrointestinal; khe: Haemolysin gene; HAI: Hospital-acquired infection; pen: Penicillin; strep: Streptomycin; met: Metronidazole; SGF: Sarcoma grow factor; SDS: Sodium dodecyl sulfate; MW: Molecular weight; DNA: Deoxyribonucleic acid; RNA: Ribonucleic acid; cDNA: Complementary Deoxyribonucleic acid; qRT-PCR: Qualitative real-time polymerase chain reaction; CFU: Colony-forming unit.

**Acknowledgements**

Not applicable.

**Author contributions**

IK, RR carried out the experiment, derived the models, analysed samples and data, interpreted the results, drafted the manuscript, prepared the figures, edited the final version of the manuscript; ED, AM performed the experiments and analyzed the data; JK and JS edited the final version of the manuscript and contributed to the conception and design of the research; JB contributed to the initial part of the experiment related to pharmaceutics; VP contributed to the animal models and experimental layout; AR and YG contributed to the conception and design of the research, interpreted the results, and approved the final version of the manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by the Lithuanian Business Support Agency grant J05-LVPA-K-03–0011 “Antimicrobial substance for treatment of Klebsiella infections”.

**Availability of data and materials**

All data generated during this study are included in this article.

**Declarations**

**Ethics approval and consent to participate**

All procedures performed in studies involving animals were in accordance with Directive 2010/63/EU and the ethical standards of Lithuanian University of Health Sciences (approved by State Food and Veterinary Service; No. G2-119) at which the studies were conducted. This article does not contain any studies with human participants performed by any of the authors.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declared that they have no competing interests.
32. Yang SC, Lin CH, Sung CT, Fang JY. Antibacterial activities of bacteriocins: application in foods and pharmaceuticals. Front Microbiol. 2014. https://doi.org/10.3389/fmicb.2014.00241.

33. Lopetuso LR, Giorgio ME, Saviano A, Scalfaroti F, Gasbarrini A, Cammarota G. Bacteriocins and bacteriophages: therapeutic weapons for gastrointestinal diseases? Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20010183.

34. Soltani S, Hammami R, Cotter PD, Rebuffat S, Said LB, Gaudreau H, Bédard F, Biron E, Drider D, Fliss I. Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations. FEMS Microbiol Rev. 2021. https://doi.org/10.1093/femsre/fuaa039.

35. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol. 2008;60(1):63–70.

36. Hatton GB, Yadav V, Basit AW, Merchant HA. Animal farm: considerations in animal gastrointestinal physiology and relevance to drug delivery in humans. J Pharm Sci. 2015;104(9):2747–76.

37. Kohl JD, Stengel A, Samuni-Blank M, Dearing MD. Effects of anatomy and diet on gastrointestinal pH in rodents. J Exp Zool A Ecol Genet Physiol. 2013;319(4):225–9.

38. Shimizu K, Seiki I, Goto Y, Murata T. Measurement of the intestinal pH in mice under various conditions reveals alkalinization induced by antibiotics. Antibiotics (Basel). 2021. https://doi.org/10.3390/antibiotics10020180.

39. Carpena N, Richards K, Gonzalez TDJB, Blas AB, Housden NG, Gerasimidis K, Milling SWF, Douse G, Malik DJ, Walker D. Targeted delivery of narrow-spectrum protein antibiotics to the lower gastrointestinal tract in a murine model ofEscherichia coli colonization. Front Microbiol. 2021. https://doi.org/10.3389/fmicb.2021.670535.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.